Chromatographic Separation of Derivatives of 4‐Alkoxy‐6‐methyl‐1H‐pyrrolo[3,4‐c]pyridine‐1,3(2H)‐dione by TLC and HPLC

References

• Śladowska , H. , Filipek , B. , Szkatuła , D. , Sabiniarz , A. , Kardasz , M. , Potoczek , J. , Sieklucka‐Dziuba , M. , Rajtar , G. , Kleinrok , Z. and Lis , T. 2002 . Investigations on the synthesis and pharmacological properties of 4‐alkoxy‐2‐[2‐hydroxy‐3‐(4‐aryl‐1‐piperazinyl)‐propyl]‐6‐methyl‐1H‐pyrrolo[3,4‐c]pyridine‐1,3(2H)‐diones . Farmaco , 57 : 897 – 908 .
   PubMedGoogle Scholar
• Śladowska , H. , Filipek , B. , Szkatuła , D. , Sapa , J. , Bednarski , M. and Ciołkowska , M. 2005 . Investigations on the synthesis and pharmacological properties of N‐substituted derivatives of 4‐alkoxy‐6‐methyl‐1H‐pyrrolo[3,4‐c]pyridine‐1,3(2H)‐diones . Farmaco , 60 : 53 – 59 .
   PubMedGoogle Scholar
• Muszalska , I. 2004 . Kinetics of hydrolysis of 4‐methoxy‐2‐[2‐hydroxy‐3(4‐phenyl‐1‐piperazinyl)]propyl‐2,3‐dihydro‐6‐methyl‐1,3‐dioxo‐1H‐pyrrolo[3,4‐c]pyridine in aqueous solutions . Farmaco , 59 : 437 – 442 .
   PubMedGoogle Scholar
• Muszalska , I. and Wituła , K. 2005 . The influence of pH and temperature on the degradation kinetics of 4‐methoxy‐2‐[3(4‐phenyl‐1‐piperazinyl)]propyl‐2,3‐dihydro‐6‐methyl‐1,3‐dioxo‐1H‐pyrrolo[3,4‐c]pyridine in aqueous solutions . Acta Polon. Pharm.–Drug Res. , 62 : 83 – 89 .
   PubMedGoogle Scholar
• Muszalska , I. and Wojtyniak , E. Stability of 4‐ethoxy‐2‐[2‐hydroxy‐3‐(4‐phenyl‐1‐piperazinyl)]propyl‐2,3‐dihydro‐6‐methyl‐1,3‐dioxo‐1H‐pyrrolo[3,4‐c]pyridine in aqueous solutions . Acta Polon. Pharm.–Drug Res. In press ,
   Google Scholar
• Muszalska , I. , Śladowska , H. and Szkatuła , D. 2003 . A validated spectrophotometric and liquid chromatography method for determination and purity evaluation of 4‐methoxy‐2‐[2‐hydroxy‐3(4‐phenyl‐1‐piperazinyl)]propyl‐2,3‐dihydro‐6‐methyl‐1,3‐dioxo‐1H‐pyrrolo[3,4‐c]pyridine] . Farmaco , 58 : 513 – 519 .
   PubMedGoogle Scholar
• Muszalska , I. , Śladowska , H. and Sabiniarz , A. 2005 . HPLC and TLC methodology for determination or purity evaluation of 4‐methoxy‐2‐[3(4‐phenyl‐1‐piperazinyl)]propyl‐2,3‐dihydro‐6‐methyl‐1,3‐dioxo‐1H‐pyrrolo[3,4‐c]pyridine] . Acta Polon. Pharm.–Drug Res. , 62 : 3 – 10 .
   PubMedGoogle Scholar
• Muszalska , I. , Śladowska , H. and Szkatuła , D. 2005 . Quantitative determination of 4‐ethoxy‐2‐[2‐hydroxy‐3(4‐phenyl‐1‐piperazinyl)]propyl‐2,3‐dihydro‐6‐methyl‐1,3‐dioxo‐1H‐pyrrolo[3,4‐c]pyridine applying high‐performance liquid chromatography with UV detection. Studies on degradation mechanism . Chem. Anal. , 50 : 875 – 886 .
   Google Scholar
• Krenn , M. , Gamcsik , M. P. , Vogelsang , G. B. and Colvin , O. M. 1992 . Improvements In solubility and stability of thalidomide upon complexation with hydroxypropyl‐β‐cyclodextrin . J. Pharm. Sci. , 81 : 685 – 689 .
   PubMed Web of Science ®Google Scholar
• Hess , S. , Akermann , M. A. , Wnedt , S. , Zwingenberger , K. and Eger , K. 2001 . Synthesis and immunological activity of water‐soluble thalidomide prodrugs . Bioorg. Med. Chem. , 9 : 1279 – 1291 .
   PubMed Web of Science ®Google Scholar
• Toraño , J. S. , Verbon , A. and Guchelaar , H. J. 1999 . Quantitative determination of thalidomide in human serum with high‐performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection . J. Chromatogr. B , 734 : 203 – 210 .
   PubMed Web of Science ®Google Scholar
• Eriksson , T. , Björkman , S. , Roth , B. , Björk , H. and Höglund , P. 1998 . Hydroxylated metabolites of thalidomide: formation in vitro and in‐vivo in man . J. Pharm. Pharmacol. , 50 : 1409 – 1416 .
   PubMed Web of Science ®Google Scholar
• Goldthwaite , Ch.A. , Hsieh , F. Y. , Womble , S. W. , Nobes , B. J. and Blair , I. A. 1996 . Liquid chromatography/chemical reaction interface mass spectrometry as an alternative to radioisotopes for quantitative drug metabolism studies . Anal. Chem. , 68 : 2996 – 3001 .
   PubMed Web of Science ®Google Scholar
• Khedr , A. and Sakr , A. 1999 . Stability‐indicating high‐performance liquid chromatographic assay of buspirone HCl . J. Chromatogr. Sci. , 37 : 462 – 468 .
   PubMed Web of Science ®Google Scholar
• Płotkowiak , Z. and Popielarz‐Brzezińska , M. 2000 . Kinetics of thermal decomposition of buspirone hydrochloride in solid state . Acta Polon. Pharm.–Drug Res. , 57 : 63 – 65 .
   PubMedGoogle Scholar
• Kobylińska , K. , Cendrowska , I. , Kobylińska , M. and Barlińska , M. 2000 . High‐performance liquid chromatographic analysis for the determination of buspirone analogue–mesmar in rat plasma . Acta Polon. Pharm.–Drug Res. , 57 : 65 – 67 .
   PubMedGoogle Scholar
• Ary , K. , Róna , K. , Ondi , S. and Gachályi , B. 1998 . High‐performance liquid chromatographic method with coulometric detection for determination of buspirone in human plasma by means of a column‐switching technique . J. Chromatogr. A , 797 : 221 – 226 .
   PubMed Web of Science ®Google Scholar
• Róna , K. , Ary , K. , Ondi , S. and Gachályi , B. 1998 . Validated liquid chromatographic method for the determination of N‐3‐(2,2,5,5‐tetramethyl‐3‐pirrolin‐3‐carboamidopropylphtalimide hydrochloride), a novel antiarrhythmic agent in human plasma . J. Chromatogr. A , 797 : 265 – 270 .
   PubMed Web of Science ®Google Scholar
• Pyka , A. , Gurak , D. , Bober , K. , Klimczok , W. and Janikowska , G. 2005 . Influence of the mobile and stationary phases on the separation of selected essential oil components and aroma substances investigated by TLC . J. Liq. Chromatogr. & Rel. Technol. , 28 : 2525 – 2537 .
   Web of Science ®Google Scholar